

FORM OF FINAL TERMS

FINAL TERMS DATED 20.09.2024

10C PCC

(incorporated in Jersey)

Acting in respect of 10C Cell 9 PC

Issue of

AWMZ SP3 PZ Tracker (the **Securities**)

ISIN: CH1377533836

pursuant to the Issuer's

Structured Products and Certificates Program

This document constitutes the Final Terms of the Securities of the Product described herein.

PART A – CONTRACTUAL TERMS

Terms used herein shall be deemed to be defined as such for the purposes of the Terms and Conditions of the Securities (the **Terms and Conditions**) issued by 10C PCC on behalf of 10C Cell 9 PC (the **Issuer**) set forth in the Base Prospectus dated 20.12.2023 as amended by a supplement dated 29.02.2024 (the **Base Prospectus**). This document constitutes the Final Terms of the Securities described herein and must be read in conjunction with the Base Prospectus (and any supplement thereto). Full information on the Issuer and the offer of the Securities is only available on the basis of the combination of these Final Terms and the Base Prospectus. The Base Prospectus (together with any supplement thereto) is available for viewing at the registered office of the Paying Agent and on the website www.bankfrick.li. The Final Terms will be available for viewing at the registered office of the Paying Agent and on the website www.bankfrick.li.

The Base Prospectus, together with the Final Terms, constitutes the prospectus with respect to the Securities described herein for the purposes of the Regulation (EC) 2017/1129 (the "Prospectus Regulation")

The JFSC has granted consent to the Issuer under Article 4 of the Control of Borrowing (Jersey) Order 1958.

Issue Date	30.09.2024
Issue Size	Up to 1'000'000 products (with reopening clause)
Security Type	Debt instrument (Products)
Initial Issue Price	USD 1000.- per product
Underlying	AWMZ GLOBAL MARKETS 3 PZ SP
Basket	applicable
Index	not applicable
Base Currency	USD
Settlement Currency	USD
Underlying	AWMZ GLOBAL MARKETS 3 PZ SP

	(a segregated portfolio/Fund of the AWMZ Global Investments SPC, an open-ended investment fund established as an exempted segregated portfolio company limited by shares in the Cayman Islands) Investment Manager(s) Aquila AG Bahnhofstrasse 43 CH-8001 Zurich Switzerland Investment Advisor(s) Aquila Wealth Management AG Summelenweg 91 CH-8808 Pfaffikon Switzerland Administrator IFINA (UK) Limited 6 The Court, Holywell Business Park Northfield Road, Southam Warwickshire, CV47 0FS United Kingdom Custodian/Deposit Bank Liechtensteinische Landesbank AG Städtle 44, P.O. Box 384 9490 Vaduz Liechtenstein Auditors Baker Tilly (Cayman) Limited Governor's Square 23 Lime Tree Bay Avenue P.O. Box 888 Grand Cayman KY1-1103 Cayman Islands
Reference Source(s) for Underlying prices	The Reference Source(s) for the price of the Underlying are: Bloomberg / NAV Statement from Fund Administrator IFINA (UK) Limited
Hedging Arrangements	not applicable
Redemption Amount	Paying Agent & Calculation Agent: Bank Frick has been appointed as both the Paying Agent and Calculation Agent for the Products. In these capacities, Bank Frick will be responsible for payment-related matters and for the calculation of the Net Asset Value (NAV) of the Products. Net Asset Value (NAV) Calculation: The NAV represents the per-note value of the assets within the actively managed certificate. Bank Frick, as the Calculation Agent, will determine the NAV on a weekly basis in accordance with recognized and standard industry valuation methodologies and practices.

	Redemption Amount Calculation: Investors wishing to redeem their Products may do so at the NAV price determined by the Calculation Agent. The Redemption Amount is calculated as follows: $\text{NAV} = (\text{Total Assets} - \text{Total Fees}) \div \text{Total Outstanding Products}$ Where: Total Assets represent the aggregate value of all assets held within the basket. Total Fees encompass all applicable fees and charges associated with the management, operation, and administration of the product. Total Outstanding Products refers to the number of products that are currently issued and not redeemed. The Redemption Amount per note will be the NAV as calculated above. Investors will receive this amount for each note they wish to redeem, subject to any additional fees or charges as outlined elsewhere in this document. Additional Fees: The Redemption Amount may also be subject to additional fees related to the transfer of fiat assets. Investors should consult the fee schedule or inquire directly to get a comprehensive understanding of any potential costs or charges associated with the redemption process. Redemption Process: Investors wishing to redeem their Products should initiate the redemption process with the Trading Desk of Bank Frick & Co. AG (trading@bankfrick.li; 00423 388 21 25). All redemptions will be processed in accordance with the terms and conditions stipulated in this document and any associated agreements.
Cut off (redemptions)	Thursday 18:00 CET
Maturity Date	n/a, this is an open-ended Product
Investor Redemption Date (put date)	Weekly, Thursday
Cash Settlement	yes
Amount of any expenses and taxes specifically charged to the subscriber or purchaser	Except as set out in the Base Prospectus ("Fees related to the Products"), all expenses related to the services provided by the service providers are included in the Investor Fee.
Yield / Yield Calculation Method	not applicable
Initial Valuation Date	07.10.2024
Valuation Frequency	Weekly / Monday (with closing prices Friday)
Settlement Cycle (for subscriptions and redemptions)	T = Monday TD = T VD = T+2 business days If the valuation date is a bank holiday, the next following business day is assumed to be the valuation date (T).
Minimum Investment Amount	USD 100'000

Minimum Trading Lot	1 Unit
Investor Fee	The Investor Fee is comprised as follows: • One-off set-up Fee CHF 8'000.- • Management fee of 0% p.a. • Administration fee of CHF 0.00 p.a. (total on product level, not per investor) • Service fee of 0.40 % p.a. (min. USD 15'000.- p.a.) Fees related to the Products will be collected in USD. Fees relating to trading and custody are charged directly to the Basket.
Distribution Fee	Up to 3%
Other Fees	n.a.
Specific Product Risks	For reasons of transparency, the following risks were taken from the prospectus of the Underlying (being the Underlying referred above and referred as the “Fund” or “fund” within the Specific Product Risks and Investment Strategy within these final terms) and are therefore to be considered from the fund's perspective. As with all investments, risk cannot be eliminated and there can be no assurance or guarantee that the Issuer will meet its objective in respect of the Fund. Investment in the Issuer is only available to investors who fully understand and are willing to assume the risks involved. Below are certain specific risk factors that must be taken into consideration before investing in Participating Shares of the Fund. While the Directors believe the following to be the most significant, this list is not intended to be exhaustive. Other potential general risk factors are detailed in the Information Memorandum. <u>Achievement of the Issuer’s Investment Objective in relation to the Fund.</u> No assurance can be given that the Issuer will achieve its overall investment objective in relation to the Fund of seeking a high total rate of return and appreciation of capital. There can be no assurance that the Investment Manager will be able to allocate the Fund’s assets in a manner that is profitable to the Fund. In addition to market risk, there is unpredictability as to changes in general economic conditions which may affect the profitability of the Fund’s investment programme. With respect to the investment strategies utilized by the Investment Manager, there is always some, and occasionally a significant, degree of market risk. <u>Dependence on the Investment Manager</u> The success of the Fund is highly dependent upon the expertise and abilities of the Investment Manager who has investment discretion over the Fund’s assets invested with them. <u>Futures Contracts</u> The Investment Manager may trade futures contracts in relation to the Fund subject to all applicable rules and regulations. The use of futures is a highly specialized activity which involves investment strategies and risks different from those associated with ordinary portfolio securities transactions, and there can be no guarantee that their use will increase the Fund’s return or not cause the Fund to sustain large losses. If the Investment Manager applies a strategy at an inappropriate time or judges market conditions or trends incorrectly, futures strategies may lower the Fund’s return or cause substantial losses. Certain strategies limit the Fund’s possibilities to realize gains as well as limit its exposure to losses. The Fund could also experience losses if the Investment Manager could not close out its positions because of an illiquid market. In addition, the Fund will incur transaction costs, including brokerage commissions, in connection with its futures transactions and these transactions could significantly increase the Fund’s investment turnover rate.

Futures Commission Merchants

The Fund's assets used to trade futures will be maintained at Futures Commission Merchants ("FCM(s)"). Under CFTC regulations, FCMs are required to maintain customer assets in a segregated account. If any FCM fails to do so, the Fund may be subject to risk of loss of funds in the event of its bankruptcy. Even if such funds are properly segregated, the Fund may still be subject to a risk of a loss of its funds on deposit with the FCM should another customer of the FCM or the FCM itself fail to satisfy deficiencies in such other customer's accounts. Bankruptcy law applicable to all U.S. futures brokers requires that, in the event of the bankruptcy of such a broker, all property held by the broker, including certain property specifically traceable to the customer, will be returned, transferred or distributed to the broker's customers only to the extent of each customer's pro-rata share of all property available for distribution to customers. If any futures broker retained in relation to the Fund were to become bankrupt, it is possible that the Fund would be able to recover none or only a portion of its assets held by such futures broker. Further, there may be instances where there is no property for such a distribution, which would result in a total loss of the Fund's assets.

Restrictions on Transfer of Participating Shares

Participating Shares are subject to restrictions limiting transferability. Participating Shares have not been registered or qualified for offer or sale under the laws of any jurisdiction. The Directors have the discretion to prohibit, even arbitrarily, a transfer of Participating Shares. As a result of these considerations, investors might not be able to liquidate their investments quickly.

Indemnity of the Directors, the Investment Manager, the Administrator etc.

The Directors, the Investment Manager, the Administrator and other agents of the Fund are entitled to be indemnified in certain circumstances. As a result, there is a risk that the Fund's assets will be used to indemnify such persons or their employees or to satisfy their liabilities as a result of their activities in relation to the Fund.

Dividend Policy

The Issuer currently does not intend to pay dividends in relation to the Fund. It is presently intended that all earnings will be reinvested. Accordingly, investors having a need for current income should not invest in the Fund.

Illiquidity of Participating Shares

There will be no secondary market for Participating Shares, and consequently, Shareholders can dispose of Participating Shares only by means of redemption. Since there is no assurance that the Issuer will be able to liquidate the assets attributable to Participating Shares without losses, a holder of Participating Shares may incur a loss upon redemption of Participating Shares. In the event of unsettled market conditions, the Issuer may be unable to redeem Participating Shares.

Lack of Independent Experts Representing Investors

The Investment Manager has consulted with counsel, accountants, and other experts regarding the Fund and its operations. Each prospective investor should consult his own legal, tax and financial advisors regarding the desirability of an investment in the Fund.

Mandatory Redemptions

The Directors have the right to require the compulsory redemption of all or any of the Participating Shares held by a Shareholder if they determine that the Participating Shares are held for the benefit of any non-qualified Shareholder. The Directors also reserve the right to require compulsory redemption of all or any of the Participating Shares held by a Shareholder if the ownership of the Participating Shares by the

Shareholder is unlawful or may be harmful or injurious to the business or reputation of the Issuer or the Investment Manager,

General Risks of Investing

An investment in the Fund is subject to all risks incidental to the ownership of the investments which the Fund may own. These factors include, without limitation, changes in government rules and fiscal and monetary policies, changes in laws and political and economic conditions throughout the world, and changes in general market conditions. There can be no guarantee that any profits will be realized by Shareholders. Under certain circumstances, the Investment Manager may be unable to liquidate investments in relation to the Fund due to the absence of a liquid market, and consequently, the Issuer may not be able to redeem Participating Shares.

Operating History

As of hereof, the Issuer has no operating history in relation to the Fund. The Fund's prospects must be considered in light of such risks, problems, delays and expenses encountered in a new business. There can be no assurance that the Issuer's activities in relation to the Fund will be successful or profitable.

Multiple Accounts and Programmes

The Investment Manager may manage and trade other accounts. Other accounts may pay different fees or be subject to different brokerage and other expenses than in relation to the Fund. The Investment Manager will not, however, knowingly or deliberately employ a trading method on behalf of any account which it manages or trades which it knows to be inferior to any trading method which it employs for any other account or knowingly or deliberately favour one account over any other account.

The Investment Manager and its affiliates may trade investments for their own accounts and for the accounts of such affiliates. Such proprietary or experimental trading may differ from the trading strategy employed on behalf of the Fund. Because trading for such proprietary or experimental accounts may be carried out pursuant to different approaches or strategies, trades for such accounts may occur before trades for the Fund's accounts or may be opposite to or ahead of those of the Fund.

Past Performance Information

Market conditions and trading approaches are continually changing, and the fact that the Investment Manager happened to be successful in the past may be largely irrelevant to its prospects for future profitability. Past results are not necessarily indicative of future performance. No assurance can be made that profits will be achieved or that substantial or total losses will not be incurred.

Redemption of Participating Shares

Substantial redemption of Participating Shares could require the Investment Manager to liquidate positions in relation to the Fund more rapidly than would otherwise be desirable, which could adversely affect the value of the Participating Shares. In these and other exceptional circumstances the Issuer may defer redemptions. Substantial redemptions might also cause the liquidation of the Fund.

Debt Securities


The Investment Manager may invest in both investment grade and sub-investment grade debt securities on behalf of the Fund some of which may be inflation linked in the expectation that positive returns can be made. For investment grade securities this will normally be with an assumption that the issuer will be able to make payment of interest and/or principal which will be part of the returns together with any appreciation of the debt security. For sub-investment grade securities or debt securities that are distressed, payments of interest or of principal may or may not be assumed but there could be other opportunities to generate a positive return from an investment. Sub-investment grade debt securities are subject to a greater risk of loss of principal and interest than higher-rated debt securities. The Issuer may invest

	in distressed debt securities on behalf of the Fund which are subject to a significant risk of the issuer's inability to meet principal and interest payments on the obligations and may also be subject to price volatility due to such factors as interest rate sensitivity, market perception of the creditworthiness of the issuer and general market liquidity risk. The Investment Manager may invest in debt securities on behalf of the Fund which rank junior to other outstanding securities and obligations of the issuer, all or a significant portion of which may be secured on substantially all of that issuer's assets. The Investment Manager may also invest in debt securities on behalf of the Fund that are not protected by financial covenants or limitations on additional indebtedness and may invest in debt securities or obtain exposure to those debt securities by selling the securities short. The issuers of debt securities may default on their obligations, whether due to insolvency, bankruptcy, fraud or other causes and their failure to make the scheduled payments could cause the Fund to suffer significant losses. The Fund will therefore be subject to credit, liquidity and interest rate risks. In addition, evaluating credit risk for debt securities involves uncertainty because credit rating agencies throughout the world have different standards, making comparison across countries difficult. Also, the market for debt securities may be inefficient and illiquid, making it difficult to accurately value financial instruments. <u>Undervalued/Overvalued Securities</u> The Investment Manager may identify and invest in undervalued and overvalued securities ("mis-valued securities") on behalf of the Fund. The identification of investment opportunities in mis-valued securities is a difficult task, and there can be no assurance that such opportunities will be successfully recognised. While purchases of undervalued securities and short sales of overvalued securities offer opportunities for above-average capital appreciation, these investments involve a high degree of financial risk and can result in substantial losses. Returns generated from the Fund's investments may not adequately compensate for the business and financial risks assumed. The Investment Manager may make certain speculative investments in securities on behalf of the Fund which the Investment Manager believes to be mis-valued; however, there can be no assurance that the securities purchased and sold will in fact be mis-valued. In addition, the Investment Manager may be required to maintain positions in such securities on behalf of the Fund for a substantial period of time before realising their anticipated value. During this period, a portion of the Fund's capital may be committed to the securities, thus possibly preventing the Issuer from investing in other opportunities on behalf of the Fund. In addition, the Issuer may finance any such purchases on behalf of the Fund with borrowed funds and thus will have to pay interest on such funds during such waiting period. <u>Derivatives Generally</u> The Issuer may utilise both exchange-traded and over-the-counter derivatives on behalf of the Fund, including, but not limited to, futures, forwards, swaps, options and contracts for differences, as part of its investment policy. These instruments can be highly volatile and expose investors to a high risk of loss. The low initial margin deposits normally required to establish a position in such instruments permit a high degree of leverage. As a result, depending on the type of instrument, a relatively small movement in the price of a contract may result in a profit or a loss which is high in proportion to the amount of funds actually placed as initial margin and may result in unquantifiable further loss exceeding any margin deposited. In addition, daily limits on price fluctuations and speculative position limits on exchanges may prevent prompt liquidation of positions resulting in potentially greater losses. Transactions in over-the-counter contracts may involve additional risk as there is no exchange market on which to close out an open position. It may be impossible to liquidate an existing position, to assess the value of a position or to assess the exposure to risk. Contractual asymmetries and inefficiencies can also increase risk, such as break clauses, whereby a counterparty can terminate a transaction on the basis of a certain reduction in Net Asset Value, incorrect collateral calls or delays in collateral recovery. The Issuer may also sell covered and uncovered options on securities on behalf of
--	--

	the Fund. To the extent that such options are uncovered, the Fund could incur an unlimited loss. THE FOREGOING LIST OF RISK FACTORS DOES NOT PURPORT TO BE A COMPLETE ENUMERATION OR EXPLANATION OF THE RISKS INVOLVED IN AN INVESTMENT IN THE ISSUER/FUND. PROSPECTIVE INVESTORS SHOULD READ THIS ENTIRE INFORMATION MEMORANDUM AND CONSULT THEIR OWN COUNSEL AND ADVISERS BEFORE DECIDING TO INVEST IN THE ISSUER/FUND.
Calculation Agent	Bank Frick & Co. AG, 9496 Balzers, Liechtenstein Bank Frick has been family-owned since its founding as a licensed full-service bank in 1998 and operates with an entrepreneurial approach. Today, the bank is 100% controlled by the Kuno Frick Family Foundation (KFS). Bank Frick specializes in banking for professional clients, offering a fully integrated range of classic and blockchain banking services. In the field of regulated blockchain banking, Bank Frick is a European pioneer, providing services such as the trading and custody of crypto-assets as well as token sales. Their classic banking offerings encompass services in the capital markets sector, as well as services for funds and issuances with a focus on the design of European (AIF, UCITS), and national fund solutions. Additional information about the custodian bank (e.g., annual reports, brochures, etc.) can be obtained directly at their headquarters or online on their website at www.bankfrick.li.
Index Calculation Agent:	not applicable
Administrator	Vistra Fund Services Limited, 4th Floor, St Paul's Gate, 22-24 New St, St Helier, Jersey JE1 4TR, Jersey
Custodian / Broker	General custodian: Bank Frick & Co. AG, 9496 Balzers, Liechtenstein
Paying Agent	Bank Frick & Co. AG, 9496 Balzers, Liechtenstein
Security Agent	Vistra (UK) Limited, 7th Floor 50 Broadway, London, United Kingdom, SW1H 0DB
Investment Manager	Aquila Wealth Management AG, Summelenweg 91, 8808 Pfäffikon SZ, Switzerland
Investment Strategy	Asset Allocation Underlying fund (according to point 'underlying'): 0-100% Cash: 0-100% Investment Strategy Underlying fund: The investment approach of the Issuer in relation to the Fund will be to invest in a spectrum of asset classes combining portfolios with conservative, balanced and dynamic characteristics. The Investment Manager will adopt a global approach when assessing and selecting investments opportunities and the portfolio make up comprise securities associated with the major financial markets, as well as emerging markets, including: Traditional direct investments in securities and similar financial instruments, such as equity securities (shares, profit participation certificates, participation certificates, etc.) traded on a stock exchange or other regulated market open to the public by companies worldwide; Debt securities and debt securities (bonds, bonds, debentures, bonds with warrants, convertible bonds, fund-linked notes with capital guarantee, etc.) traded on a stock exchange or other regulated market open to the public, by private and public debtors worldwide and denominated in a freely convertible currency;

	Money market instruments, if they are liquid and assessable and are traded on a stock exchange or other regulated market open to the public and money market instruments that are not traded on a stock exchange. Traditional indirect investments in transferable securities and similar financial instruments. Units or shares of open-ended collective investment. Index certificates and index baskets or other derivative financial instruments; Exchange traded funds ("ETFs", also known as "index tracking stocks"). Indirect investments in real estate, including units or shares of domestic and foreign real estate investment funds or undertakings for collective investment with a similar function from an OECD member state that are subject to state supervision, as well as equity securities and equity securities of real estate companies (including REITs, real estate investment trusts) worldwide that are listed on a stock exchange or other regulated publicmarket. The Investment Manager may also invest the Fund's assets in derivative instruments, such as forex forward contracts, interest rates swaps, cross currency swaps, long options and short options, futures contracts (including commodities, currency and equity indices) and cryptocurrencies.
Market Maker	applicable / not applicable
Exchange	not applicable
Significant or material change statement	There has been no significant change in the financial or trading position of the Issuer and there has been no material adverse change in the financial position or the prospects of the Issuer since 20.12.2023.
Responsibility	The Issuer has taken all reasonable care to ensure that the facts stated herein are true and accurate in all material respects, and that there are no other facts the omission of which would make misleading any statement in these Final Terms. Accordingly, the Issuer accepts responsibility for the information contained in these Final Terms.
Date of Board of Directors approval of issuance	20.09.2024

Signed on behalf of the Issuer as duly authorized representative:

DocuSigned by:

 By: 4F5B570733C0476...

PART B – OTHER INFORMATION

Listing and admission to trading	not applicable
Interests of natural and legal persons involved in the issue	So far as the Issuer is aware, no person involved in the offer of the Securities has an interest material to the offer
Third Party Information	not applicable
Additional Selling Restrictions	not applicable
Distribution / Authorized Offerors	An offer of the Securities may be made only by authorized offerors (the Authorized Offerors) in or from any jurisdiction in circumstances which will result in compliance with any applicable laws and regulations and which will not impose any obligation on the Issuer. Offers of the Securities are conditional upon their issue and, as between the Authorized Offeror and their customers, any further conditions as may be agreed between them. The following financial intermediary/ies qualifies as an Authorized Offeror and shall be authorized to use the Base Prospectus, as completed by these Final Terms: Securities firms and banks that are able to settle creations and / or redemptions directly or indirectly through SIX SIS AG with the Paying Agent
Security Codes	Valoren: 137753383 ISIN: CH1377533836
Clearing Systems	SIX SIS
Terms and Conditions of the Offer	Securities are made available by the Issuer for subscription only to the Eligible Investors
Offer Period	Until end of validity of the Base Prospectus
Offer Price	Offer Price is the applicable value calculated in accordance with the calculation methodology applicable to the calculation of the Redemption Amount.
Conditions to which the offer is subject	Offers of the Products are conditional upon their issue and, as between the Authorised Offeror(s) and their customers, any further conditions as may be agreed between them. An Investor intending to acquire any Products is asked to consult his security house or bank whether the Products can be made available.
Details of the minimum and/or maximum amount of application	not applicable
Details of the method and time limited for paying up and delivery the Securities	not applicable
Manner in and date on which results of the offer are made available to the public	not applicable
Procedure for exercise of any right of pre-emption, negotiability of subscription rights and treatment of subscription rights not exercised:	not applicable
Whether tranche(s) have been reserved for certain countries	not applicable

Process for notification to applicants of the amount allotted and the indication whether dealing may begin before notification is made	not applicable
Name(s) and address(es), to the extent known to the Issuer, of the places in the various countries where the offer takes place	EU / EEA / Switzerland
Name and address of financial intermediary/ies authorized to use the Base Prospectus, as completed by these Final Terms (the Authorized Offerors)	Securities firms and banks that are able to settle creations and / or redemptions directly or indirectly through SIX SIS AG with the Paying Agent

ISSUE-SPECIFIC SUMMARY

A. Introduction and Warnings

10C PCC (the “PCC”) with its registered office at 4th Floor, St Paul’s Gate, 22-24 New Street, St Helier, Jersey JE1 4TR, cs.je@vistra.com, phone +44 1534 504 700, with registration number 149624 and LEI 2138005684QJK2QTKX27 issues structured notes including actively managed certificates which may or may not be exchange traded under the Structured Notes and Certificates Program (the “Program”) on the basis of a Base Prospectus dated 15.12.2023 in conjunction with Final Terms specific to the issue of each Product.

The Base Prospectus was approved by the Finanzmarktaufsicht Liechtenstein, Landstrasse 109, Postfach 279, 9490 Vaduz (info@fma-li.li) on 15.12.2023. These Final Terms relating to the **AWMZ SP3 PZ Tracker** have been filed with the FMA on 16.02.2024 and will, together with the Base Prospectus, be made available at the registered office of the Paying Agent at <https://www.bankfrick.li/en/services/fund-and-capital-markets/capital-markets>

This overview contains a description of the main features and risks relating to the Issuer, the securities offered under the Program and these Final Terms and the counterparties. The summary should always be read together with the Base Prospectus (as supplemented) and the Final Terms for a specific Product. A thorough examination of the full Base Prospectus and the Final Terms is therefore recommended prior to any decision to purchase or subscribe to Products issued under the Program. Investors have to consider that they are about to invest in financial products which are complex and not easy to understand, and which bear the risk that Investors may lose all or part of the invested capital. The Issuer points out that in the event that claims are brought before a court based on the information contained in the Base Prospectus, the Final Terms or this summary the plaintiff investor may, under national law of the member states of the European Economic Area (EEA), have to bear the costs of translating the Base Prospectus and the Final Terms prior to the commencement of proceedings. In addition, the Issuer points out that the **Issuer 10C PCC acting on behalf of 10C Cell 9 PC** who has tabled the summary including any translation thereof may be held liable in the event that the summary is misleading, inaccurate or inconsistent when read together with the Base Prospectus or the Final Terms or where it does not provide, when read together with the Base Prospectus or the Final Terms, key information in order to aid investors when considering whether to invest in the securities.

B. Key Information on the Issuer

1. Who is the Issuer of the Securities?

The issuer of the Products is **10C PCC acting on behalf of 10C Cell 9 PC**. The PCC is a protected cell company under the Jersey Companies Law and was incorporated and registered in Jersey on 10 July 2023 for an unlimited duration with Jersey registration number 149624. The registered office of the Issuer is, 4th Floor, St Paul’s Gate, 22-24 New Street, St Helier, Jersey JE1 4TR.

The Issuer has been established as a special purpose vehicle for the purpose of issuing structured products, each time acting on behalf of one of its protected cells, and certificates linked to certain Underlying, which typically will be collateralized. The products will not be listed on exchanges or trading venues in Switzerland or the EEA.

The sole shareholder of the PCC is Vistra Fund Services Limited in its capacity as trustee (in such capacity, the Jersey Trustee) of The Pine9 Purpose Trust (the Trust). The directors of the PCC are: Marc Walter Harris, Jersey, and Alexandra Nethercott-Parkes, Jersey.

The auditors of the Issuer are Grant Thornton AG, 9494 Schaan, Principality of Liechtenstein. The financial statements of the Issuer will be established in accordance with IFRS accounting standards for the first time for the business year ending on 31 December 2023.

2. What is the key financial information regarding the Issuer?

The financial year of the Issuer ends on 31 December of each year. The Issuer was incorporated on 10 July 2023, audited financial statements will for the first time be prepared as of 31 December 2023.

3. What are the key risks that are specific to the Issuer?

The Issuer is a Special Purpose Vehicle

The Issuer is not an operating company. The Issuer is a special purpose vehicle with the sole business of issuing structured products. The contracts which may be entered into by the Issuer and the payments of the Issuer and the parties thereunder are structured to have the capacity to provide the Issuer with funds to service payments due and payable in respect of the Products and on any redemption by the Issuer of the Products.

PCC Structure

The PCC has been constituted as a protected cell company under the Jersey Companies Law. Each Series of Notes issued by the PCC (as specified in the relevant Final Terms) is a Series of Notes issued by a protected cell of the PCC. A protected cell company is a multi-cellular company whose principal feature is that each protected cell has its own distinct assets which are not available to creditors of other protected cells of that company or the company as a whole. The relevant provisions of the Jersey Companies Law have not yet been tested in the courts of Jersey, the United Kingdom or elsewhere and jurisdictions other than Jersey may not be prepared to accept that creditors of a particular Issuer are prevented from gaining access to the assets attributed to other Issuers, or that creditors of the PCC (in its own capacity) do not have access to those assets specifically designated as cellular assets. In order to minimise this risk: (i) service providers to the PCC will generally be required to agree that their fees will be paid solely from the assets of the PCC in its own capacity; and (ii) the Terms and Conditions of each Series of Notes will provide that any liability to a holder will be satisfied only out of the assets of the Issuer (being a specified protected cell). However, a court could determine that such agreements are not enforceable.

If the courts in Jersey, the United Kingdom or elsewhere were not to recognise and give effect to the segregation of PCC's and each of its protected cells' assets and the agreements with service providers and investors referred to above, and the cellular assets of any protected cell were held to be available to meet the liabilities of the PCC or any other protected cell, this could have a material and adverse effect on that protected cell's financial condition and prospects and the value of any relevant Series of Notes.

This means that if the segregation of assets of the PCC or each of its protected cells were not to be recognised, investors in the Products issued by PCC acting on behalf of a particular protected cell may have a reduced ability to recover all or part of their initial investment in the Products as their claim will be in competition with the claims of any other creditor of the PCC and any other creditor of the PCC acting on behalf of each of its other protected cells from time to time.

Credit and Insolvency Risk

Each Investor bears the general risk that the financial situation of the Issuer could deteriorate. Unless specified otherwise, Investors are exposed to the credit risk of the Issuer of the Products. The Products constitute unsubordinated obligations of the Issuer and rank *pari passu* with each other and all other current and future unsubordinated obligations of the Issuer. The insolvency of the Issuer may lead to a partial or total loss of the invested capital. Collateralization reduces the credit risk of the Issuer only to the extent that the proceeds from the liquidation of Collateral (less the costs of liquidation, including the fees and expenses of the Security Agent, and payout) meet the investors' claims. Investors bear the risks, among others, that the liquidation of the Collateral may result in insufficient liquidation proceeds or, in extreme circumstances, that the Collateral may lose its value entirely before liquidation can take place.

Competition

There are a number of other issuers for products similar to the Products, and other competitors may enter the market at any time. The effect of new or additional competition on the Products or their market prices cannot be predicted or quantified. There are several large institutions such as BlackRock iShares and Barclays iPath, which have issued similar products in the past based on other underlyings. These competitors have significantly greater financial and legal resources than the Issuer and there is no guarantee that the Issuer will be able to compete successfully, or at all, with such competitors. Moreover, increased competition may severely impact the profitability and creditworthiness of the Issuer.

Potential Conflicts of Interest

The Issuer may issue other derivative instruments relating to Underlying Components. The introduction of such competing products may affect the market value of the Products. The Issuer may also receive non-public information relating to the Underlying Components that the Issuer may not make available to Investors. The directors of the Issuer do not have any interest that conflicts with that of the Issuer.

C. Key Information on the Products

4. What are the main features of the securities?

The **AWMZ SP3 PZ Tracker** issued under the Program is a structured debt note in the form of a actively managed certificate linked to Underlying assets as specified in the Final Terms. Products issued under the Program may be linked to transferable securities (including units in investment undertakings), digital assets (including crypto currencies), components of Indices or other assets (the "Underlying") or a basket or combination of such Underlying which may or may not be hedged and may or may not have long or short exposures to the daily performance of a referenced index, all as set out in the detailed Final Terms applicable to the respective Product.

The Issuer will not invest in and will not use as Underlying certain prohibited categories of cryptocurrencies such as privacy coins, algorithmic stable coins and nonfungible tokens.

The Issuer will credit the Underlyings or Underlying Components of the Products specified in the Final Terms to a Collateral Account on the basis of a Collateral Agreement with the Security Agent for the benefit of Investors to secure the Issuer's payment obligations under the Base Prospectus and the Final Terms.

The price movement of any one Product and the movement of the aggregate value of the Underlying, which will be specified in the Final Terms, correlates 1:1, but the entitlement of the Investor will be reduced by administration fees, custody fees, index licensing fees, investment management fees and other fees as applicable due to providers of services in relation to the Products (Investor Fees) and as determined in the Final Terms. Such value may be further adjusted by tracking errors resulting from foreign currency hedging, if any.

The Products are limited-recourse obligations of the Issuer. The entitlement of investors in a Series of Notes issued by the Issuer acting on behalf of one of its protected cells (as specified in the Final Terms) will be limited to the assets attributable to such cell.

Subject to the Selling Restrictions, the Securities are freely transferable.

5. Rights attached to the securities

The Securities do not bear interest and do not have a fixed maturity date.

The Issuer can at any time decide to redeem the Products (Call Option).

Investors can demand redemption by the Issuer by directly approaching the Paying Agent. Redemption can be requested in a frequency respectively in intervals as defined in the Final Terms for each Product ("Investor Redemption Date") and will, except if stated otherwise in the Final Terms, be linked to the valuation frequency of a certain Product.

On each Investor Redemption Date (as specified in the Final Terms), an Investor holding Securities in any Product may, in case of investors other than Eligible Investors through the intermediation of an Eligible Investor, by giving a Redemption Order to the Paying Agent within the Redemption Notice Period, redeem the Securities held by such Investor.

Redemption Amount

The amount per Product payable by the Issuer upon redemption will be calculated by the Calculation Agent unless set out otherwise in the Final Terms in the Settlement Currency in accordance with the formula set out in the relevant Final Terms (the **Redemption Amount**). Settlement will occur in the form of a cash payment, investors are not entitled to demand redemption in kind.

The Products constitute unsubordinated obligations of the Issuer and rank pari passu with each other and all other current and future unsubordinated obligations of the Issuer. The insolvency of the Issuer may lead to a partial or total loss of the invested capital, regardless of the Collateral.

6. Ranking of the securities in the event of insolvency

The rights of the Investors are limited to the payment of Redemption Amounts from proceeds of the realization or enforcement of the Collateral held on a Collateral Account for the Issuer on behalf of the Cell having issued the respective Series of Notes of a Product. Rights of investors to receive payments out of such collateral proceeds will be subordinated to the payment of certain costs, fees, expenses and other amounts due in respect of the Program. In case of realization or enforcement of the Collateral, the proceeds will be applied in the applicable order of priority under which amounts due to Investors will be subordinated to certain costs, fees,

expenses and other amounts including (without limitation) the costs of liquidating the Collateral but will be senior to claims of other creditors of the Issuer.

7. Where will the securities be traded?

Products offered under this Program will not be listed or exchange traded.

8. What are the key risks that are specific to the securities?

Underlying assets

The value of Products is affected by the price and development of the Underlying or Underlying Components. The amount to be paid by the Issuer upon redemption of any Products, or, in respect of redemption, the amount of Collateral able to be redeemed, depends on the performance of these assets, as calculated in accordance with the Terms and Conditions. The Products are not capital protected at all and there is, therefore, a risk of partial or complete loss of investment.

In case of a Product referencing a basket of Underlying, the negative performance of a single component may outweigh a positive performance of other components and may have a negative impact on the return on the Products.

Liquidity

The Products will not be listed on an exchange or trading venue. Investors will therefore not be able to sell their Products except on a bilateral basis (OTC) and there is no noted market price for the products.

Execution Risk

It may be impossible to execute trades in any Underlying at the price quoted or such Underlying. Any discrepancies between the quoted price and the execution price may be the result of the availability of assets, any relevant spreads or fees at the exchange or discrepancies in the pricing across exchanges. The Issuer will take all reasonable steps to ensure optimal execution, but is limited by KYC requirements, custodianship solutions and availability of exchanges. The Issuer cannot, therefore, guarantee that the price at which any trade is executed is the best available price globally.

Realization of Collateral

If the amounts received upon the realization of Collateral are not sufficient to fully cover the fees and expenses of the Program and the parties involved and the Issuer's payment obligations to Investors, then Investors may incur a loss, which may be significant.

D. Key information on the offer of the notes to the public

9. Under which conditions and timetable can I invest in this security?

The **AWMZ SP3 PZ Tracker** shall be subject to a continual issuance and redemption mechanism, under which additional Securities of such Product may be issued, and Securities may be redeemed by Investors in accordance with the Terms and Conditions.

The Issuer will accept direct subscriptions only from regulated banks or brokers domiciled in the EU / EEA, Switzerland or the United Kingdom which are entitled to directly trade through SIX SIS AG and who meet the definition of a Professional Investor under the SPB Order ("**Eligible Investors**"). Other investors may purchase Securities by directly approaching their bank or broker (provided it is or has access to an Eligible Investor) or on the secondary market over the counter (OTC).

The Issuer can at any time decide to redeem the Products (Call Option). Eligible Investors can demand redemption by the Issuer by directly approaching the Paying Agent. Redemption can be requested in a frequency respectively in intervals as defined in the Final Terms for each Product and will, except if stated otherwise in the Final Terms, typically be linked to the valuation frequency of a certain Product.

Settlement

Settlement and Clearing of trades in the Securities takes place through SIX SIS AG or any other clearing system defined in the Final Terms.

Expenses

The costs of the issue of Products under the Program will be borne by the Issuer and will not be deducted from the issue proceeds.

Investors will be charged administration fees, custody fees, index licensing fees, investment management fees, performance fees and other fees due to providers of services in relation to the Products (Investor Fees) as further specified in the relevant Final Terms.

10. Why is this Prospectus being produced?

10C PCC was set up to issue structured products, acting in respect of its protected cells, including actively managed certificates linked to certain Underlying. 10C PCC has established the Structured Notes and Certificates Program (the Program), described in this Base Prospectus, under which Products may be issued from time to time.

The proceeds of the issue of a Series of Notes will, after deduction of costs and assets required for general corporate purposes, be invested in specific Underlying which will serve as Collateral for the obligations of the Issuer under this Base Prospectus.

Net proceeds the Issuer expects to generate through the issue of Products under the Program as well as estimated costs to accrue per Product, if any, will be specified in the Final Terms and Issue Specific Summary for each Product.

Potential Conflicts of Interest

Several participants to the transactions described in the Base Prospectus and these Final Terms are identical or do have close links. The Custodian at the same time acts as Paying Agent and Calculation Agent under the Program.

Appropriate procedures have been implemented to avoid any conflicts of interests adversely affecting the interests of Investors. Fees payable to all parties as well as independent parties, are disclosed in the Base Prospectus or the Final Terms.

EMISSIONSSPEZIFISCHE ZUSAMMENFASSUNG

A. Einleitung und Warnungen

10C PCC (die «PCC») mit Sitz in 4th Floor, St Paul's Gate, 22-24 New Street, St Helier, Jersey JE1 4TR, cs.je@vistra.com, Telefon +44 1534 504 700, mit der Handelsregisternummer 149624 und LEI **2138005684QJK2QTKX27** emittiert strukturierte Anleihen, einschliesslich aktiv verwalteter Zertifikate, die im Rahmen des Programms für strukturierte Anleihen und Zertifikate (das «**Programm**») auf der Grundlage eines Basisprospekts vom 15.12.2023 in Verbindung mit den endgültigen Bedingungen, die für die Emission der einzelnen Produkte gelten, börsengehandelt sein können oder nicht.

Der Basisprospekt wurde von der Finanzmarktaufsicht Liechtenstein, Landstrasse 109, Postfach 279, 9490 Vaduz (info@fma-li.li) am 15.12.2023 genehmigt. Die vorliegenden Endgültigen Bedingungen beziehen sich auf den **AWMZ SP3 PZ Tracker** und wurden am 16.02.2024 bei der FMA hinterlegt. Die Endgültigen Bedingungen werden zusammen mit dem Basisprospekt am Sitz der Zahlstelle unter <https://www.bankfrick.li/de/services/fund-and-capital-markets/capital-markets> zur Verfügung gestellt.

Diese Übersicht enthält eine Beschreibung der wichtigsten Merkmale und Risiken in Bezug auf die Emittentin, die im Rahmen des Programms und dieser Endgültigen Bedingungen angebotenen Wertpapiere und die Gegenparteien. Die Zusammenfassung sollte immer zusammen mit dem Basisprospekt (in der ergänzten Fassung) und den endgültigen Bedingungen für ein bestimmtes Produkt gelesen werden. Es wird daher empfohlen, das vollständige Basisprospekt und die endgültigen Bedingungen vor einer Entscheidung über den Kauf oder die Zeichnung von im Rahmen des Programms emittierten Produkten gründlich zu lesen. Anleger*innen sollten bedenken, dass sie im Begriff sind, in Finanzprodukte zu investieren, die komplex und nicht einfach zu verstehen sind und die das Risiko bergen, dass sie ihr investiertes Kapital ganz oder teilweise verlieren können. Die Emittentin weist darauf hin, dass für den Fall, dass aufgrund der im Basisprospekt, den endgültigen Bedingungen oder dieser Zusammenfassung enthaltenen Informationen vor einem Gericht Ansprüche geltend gemacht werden, der klagende Anleger oder die klagende Anlegerin nach nationalem Recht der Mitgliedstaaten des Europäischen Wirtschaftsraums (EWR) möglicherweise die Kosten für die Übersetzung des Basisprospekts und der endgültigen Bedingungen vor Prozessbeginn zu tragen hat. Darüber hinaus weist die Emittentin darauf hin, dass die **Emittentin 10C PCC, die im Namen von 10C Cell 9 PC handelt** und die Zusammenfassung einschliesslich einer Übersetzung davon vorgelegt hat, haftbar gemacht werden kann, wenn die Zusammenfassung irreführend, unrichtig oder widersprüchlich ist, wenn sie zusammen mit dem Basisemissionsprospekt oder den endgültigen Bedingungen gelesen wird oder wenn sie in Verbindung mit dem Basisprospekt oder den endgültigen Bedingungen keine wesentlichen Informationen enthält, die Anleger*innen bei der Entscheidung über eine Anlage in die Wertpapiere helfen.

B. Wesentliche Informationen über die Emittentin

11. Wer ist die Emittentin der Wertpapiere?

Die Emittentin der Produkte ist **10C PCC, die im Namen von 10C Cell 9 PC handelt**. Die PCC ist eine Protected Cell Company nach dem Jersey Companies Law und wurde am 10. Juli 2023 in Jersey für eine unbefristete Dauer mit der Jersey-Handelsregisternummer 149624 gegründet und eingetragen. Der eingetragene Sitz der Emittentin ist 4th Floor, St Paul's Gate, 22-24 New Street, St Helier, Jersey JE1 4TR.

Die Emittentin wurde als Special Purpose Vehicle gegründet, um strukturierte Produkte zu emittieren, die jeweils im Namen einer ihrer Protected Cells handeln, sowie Zertifikate, die an bestimmte Basiswerte gebunden sind, die in der Regel abgesichert werden. Die Produkte werden nicht an Börsen oder Handelsplätzen in der Schweiz oder dem EWR notiert.

Alleiniger Aktionär der PCC ist Vistra Fund Services Limited in seiner Eigenschaft als Treuhänder (in dieser Eigenschaft der Jersey Trustee) des Pine9 Purpose Trust (der Trust). Die Direktoren der PCC sind: Marc Walter Harris, Jersey, und Alexandra Nethercott-Parkes, Jersey.

Die Revisionsstelle der Emittentin ist die Grant Thornton AG, 9494 Schaan, Fürstentum Liechtenstein. Die Jahresrechnungen der Emittentin wird erstmals für das am 31. Dezember 2023 endende Geschäftsjahr nach den IFRS-Rechnungslegungsstandards erstellt.

12. Wie lauten die wichtigsten Finanzinformationen über die Emittentin?

Das Geschäftsjahr der Emittentin endet am 31. Dezember eines jeden Jahres. Die Emittentin wurde am 10. Juli 2023 gegründet, geprüfte Jahresabschlüsse werden zum ersten Mal per 31. Dezember 2023 bereitgestellt.

13. Welches sind die Hauptrisiken der Emittentin?

Die Emittentin ist ein Special Purpose Vehicle.

Die Emittentin ist keine Betriebsgesellschaft. Die Emittentin ist ein Special Purpose Vehicle, dessen einziger Geschäftszweck die Emission von strukturierten Produkten ist. Die Verträge, die von der Emittentin abgeschlossen werden können, sowie die Zahlungen der Emittentin und der Vertragsparteien sind so strukturiert, dass sie der Emittentin Mittel zur Verfügung stellen, um die fälligen und zu leistenden Zahlungen in Bezug auf die Produkte und auf eine etwaige Rücknahme der Produkte durch die Emittentin zu begleichen.

PCC-Struktur

Die PCC wurde als eine Protected Cell Company nach dem Jersey Companies Law gegründet. Jede von der PCC begebene Serie von Anleihen (wie in den jeweiligen endgültigen Bedingungen angegeben) handelt es sich um Anleihen, die von einer Protected Cell der PCC emittiert werden. Eine Protected Cell Company ist ein mehrzelliges Unternehmen, dessen Hauptmerkmal darin besteht, dass jede Protected Cell über eigene Vermögenswerte verfügt, die den Gläubiger*innen anderer Protected Cells dieses Unternehmens oder des Unternehmens als Ganzes nicht zur Verfügung stehen. Die einschlägigen Bestimmungen des Jersey Companies Law wurden noch nicht vor den Gerichten Jerseys, des Vereinigten Königreichs oder anderswo erprobt, und andere Gerichtsbarkeiten als Jersey sind möglicherweise nicht bereit zu akzeptieren, dass Gläubiger einer bestimmten Emittentin daran gehindert werden, Zugang zu den Vermögenswerten zu erhalten, die anderen Emittenten zugerechnet werden, oder dass Gläubiger*innen der PCC (in ihrer Eigenschaft als solche) keinen Zugang zu den Vermögenswerten haben, die speziell als zelluläre Vermögenswerte ausgewiesen sind. Um dieses Risiko zu minimieren: (i) müssen die Dienstleister der PCC im Allgemeinen zustimmen, dass ihre Gebühren ausschliesslich aus den Vermögenswerten der PCC in ihrer eigenen Eigenschaft gezahlt werden; und (ii) sehen die Bedingungen jeder Serie von Anleihen vor, dass jegliche Haftung gegenüber einem Inhaber nur aus den Vermögenswerten der Emittentin (einer bestimmten Protected Cell) erfüllt wird. Ein Gericht könnte jedoch entscheiden, dass solche Vereinbarungen nicht vollstreckbar sind.

Sollten die Gerichte in Jersey, im Vereinigten Königreich oder anderswo die Trennung der Vermögenswerte der PCC und jeder ihrer Protected Cells sowie die oben genannten Vereinbarungen mit Dienstleistern und Anleger*innen nicht anerkennen und durchsetzen und die zellulären Vermögenswerte einer Protected Cell als verfügbar erachtet werden, um die Verbindlichkeiten der PCC oder einer anderen Protected Cell zu erfüllen, könnte dies wesentliche und nachteilige Auswirkungen auf die finanzielle Lage und die Aussichten dieser Protected Cell sowie den Wert der betreffenden Serie von Anleihen haben.

Dies bedeutet, dass Anleger*innen, die in die von der PCC im Namen einer bestimmten Protected Cell emittierten Produkte investieren, bei einer Nichtanerkennung der Vermögenstrennung der PCC oder der einzelnen Protected Cells möglicherweise weniger Möglichkeiten haben, ihre ursprüngliche Investition in die Produkte ganz oder teilweise zurückzuerhalten, da ihre Forderung mit den Forderungen aller anderen Gläubiger*innen der PCC sowie aller anderen Gläubiger*innen der PCC, die im Namen der anderen Protected Cells handeln, in Konkurrenz steht.

Kredit- und Zahlungsunfähigkeitsrisiken

Sämtliche Anleger*innen tragen das allgemeine Risiko, dass sich die finanzielle Situation der Emittentin verschlechtern könnte. Sofern nicht anders angegeben, sind die Anleger*innen dem Kreditrisiko des Emittenten der Produkte ausgesetzt. Die Produkte stellen nicht nachrangige Verbindlichkeiten der Emittentin dar und sind untereinander sowie mit allen anderen gegenwärtigen und zukünftigen nicht nachrangigen Verbindlichkeiten der Emittentin gleichrangig. Die Zahlungsunfähigkeit der Emittentin kann zu einem teilweisen oder vollständigen Verlust des investierten Kapitals führen. Die Absicherung reduziert das Kreditrisiko der Emittentin nur in dem Masse, in dem die Erlöse aus der Verwertung der Sicherheiten (abzüglich der Kosten der Verwertung, einschliesslich der Gebühren und Auslagen des Sicherheitsbeauftragten, und der Auszahlung) die Ansprüche der Anleger*innen erfüllen. Anleger*innen tragen unter anderem das Risiko, dass die Liquidation der Sicherheiten zu unzureichenden Liquidationserlösen führt oder dass die Sicherheiten im Extremfall ihren Wert vollständig verlieren, bevor die Liquidation überhaupt stattfinden kann.

Wettbewerb

Es gibt eine Reihe anderer Emittenten von Produkten, die den Produkten ähnlich sind. Zudem können jederzeit weitere Wettbewerber in den Markt eintreten. Die Auswirkungen eines neuen oder zusätzlichen Wettbewerbs auf die Produkte oder ihre Marktpreise lassen sich weder vorhersagen noch quantifizieren. Es gibt mehrere grosse Institute wie BlackRock iShares und Barclays iPath, die in der Vergangenheit ähnliche Produkte auf der Grundlage anderer Basiswerte emittiert haben. Diese Konkurrenten verfügen über wesentlich grössere finanzielle und rechtliche Ressourcen als die Emittentin, und es gibt keine Garantie dafür, dass die Emittentin in der Lage sein wird, mit diesen Konkurrenten erfolgreich oder überhaupt zu konkurrieren. Darüber hinaus kann ein verstärkter Wettbewerb die Rentabilität und Kreditwürdigkeit der Emittentin erheblich beeinträchtigen.

Potenzielle Interessenkonflikte

Die Emittentin kann weitere derivative Instrumente emittieren, die sich auf Basiswertkomponenten beziehen. Die Einführung solcher konkurrierender Produkte kann den Marktwert der Produkte beeinträchtigen. Die Emittentin

kann auch nicht-öffentliche Informationen, die sich auf die Basiswertkomponenten beziehen, erhalten, welche die Emittentin den Anleger*innen nicht zugänglich machen darf. Die Direktoren der Emittentin haben keine Interessen an Handlungen, die mit den Interessen der Emittentin in Konflikt stehen.

C. Was sind die wichtigsten Merkmale der Wertpapiere?

Bei den im Rahmen des Programms emittierten **AWMZ SP3 PZ Tracker** handelt es sich um strukturierte Schuldscheine in der Form von aktiv verwalteten Zertifikaten, die an die in den endgültigen Bedingungen genannten zugrunde liegenden Vermögenswerte gebunden sind. Die im Rahmen des Programms emittierten Produkte können an übertragbare Wertpapiere (einschliesslich Anteilen an Investmentunternehmen), digitale Vermögenswerte (einschliesslich Kryptowährungen), Komponenten von Indizes oder andere Vermögenswerte (der «Basiswert») oder einen Korb bzw. eine Kombination solcher Basiswerte gebunden sein, die abgesichert oder nicht abgesichert sein und sowohl langfristige als auch kurzfristige Risiken in Bezug auf die tägliche Wertentwicklung eines referenzierten Index aufweisen können, wie in den detaillierten endgültigen Bedingungen für das jeweilige Produkt dargelegt ist.

Die Emittentin wird die in den endgültigen Bedingungen genannten Basiswerte bzw. Basiswertkomponenten der Produkte auf der Grundlage einer Sicherheitenvereinbarung mit dem Sicherheitsbeauftragten zugunsten der Anleger*innen einem Sicherheitenkonto gutschreiben, um die Zahlungsverpflichtungen der Emittentin gemäss dem Basisprospekt und den endgültigen Bedingungen zu sichern.

Die Kursentwicklung eines Produkts und die Entwicklung des Gesamtwerts des Basiswerts, die in den endgültigen Bedingungen festgelegt wird, stehen in einem Verhältnis von 1:1. Der Anspruch der Anleger*innen wird jedoch um Verwaltungs-, Depot-, Indexlizenz-, Anlageverwaltungs- und sonstige Gebühren, die den Anbieter*innen von Dienstleistungen im Zusammenhang mit den Produkten (Anlegergebühren) zustehen und in den endgültigen Bedingungen festgelegt werden, gekürzt. Dieser Wert kann durch Tracking Error, die sich aus einer eventuellen Fremdwährungsabsicherung ergeben, weiter angepasst werden.

Bei den Produkten handelt es sich um Verbindlichkeiten mit beschränktem Rückgriffsrecht der Emittentin. Der Anspruch von Anlegenden in einer Serie von Anleihen, die von der Emittentin im Namen einer ihrer Protected Cells (wie in den endgültigen Bedingungen angegeben) emittiert werden, ist auf die Vermögenswerte beschränkt, die dieser Cell zuzuordnen sind.

Vorbehaltlich der Verkaufsbeschränkungen sind die Wertpapiere frei übertragbar.

14. Mit den Wertpapieren verbundene Rechte

Die Wertpapiere sind nicht verzinslich und haben kein festes Fälligkeitsdatum.

Die Emittentin kann jederzeit beschliessen, die Produkte zurückzukaufen (Call-Option).

Anleger*innen können die Rücknahme durch die Emittentin verlangen, indem sie sich direkt an die Zahlstelle wenden. Die Rücknahme kann in einer Häufigkeit bzw. in Intervallen beantragt werden, die in den endgültigen Bedingungen für jedes Produkt festgelegt sind («Rückzahlungsdatum für Anleger*innen»), und ist, sofern in den endgültigen Bedingungen nicht anders angegeben, an die Bewertungshäufigkeit eines bestimmten Produkts gebunden.

An jedem Rückzahlungsdatum für Anleger*innen (wie in den endgültigen Bedingungen angegeben) können Anleger*innen, die Wertpapiere in einem Produkt halten, im Falle von Anleger*innen, die keine zugelassenen Anleger*innen sind, durch die Vermittlung von zugelassenen Anleger*innen einen Rückzahlungsauftrag an die Zahlstelle innerhalb der Rückzahlungsankündigungsfrist erteilen, um die von diesen Anleger*innen gehaltenen Wertpapiere zurückzuzahlen.

Rückzahlungsbetrag

Der von der Emittentin bei Rückzahlung zu zahlende Betrag pro Produkt wird von der Berechnungsstelle, sofern in den endgültigen Bedingungen nichts anderes bestimmt ist, in der Abrechnungswährung gemäss der in den jeweiligen endgültigen Bedingungen dargelegten Formel berechnet (der **Rückzahlungsbetrag**). Die Abrechnung erfolgt in Form einer Barzahlung. Die Anleger*innen sind nicht berechtigt, eine Rückzahlung in Form von Sachleistungen zu verlangen.

Die Produkte stellen nicht nachrangige Verbindlichkeiten der Emittentin dar und sind untereinander und mit allen anderen gegenwärtigen und zukünftigen nicht nachrangigen Verbindlichkeiten der Emittentin gleichrangig. Die

Zahlungsunfähigkeit der Emittentin kann unabhängig von den Sicherheiten zu einem teilweisen oder vollständigen Verlust des investierten Kapitals führen.

15. Rangfolge der Wertpapiere im Falle der Zahlungsunfähigkeit

Die Rechte der Anleger*innen sind auf die Zahlung von Rückzahlungsbeträgen aus den Erlösen der Verwertung oder Vollstreckung der Sicherheiten beschränkt, die auf einem Sicherheitenkonto für die Emittentin im Auftrag der Cell, welche die jeweilige Serie von Anleihen eines Produkts emittiert hat, gehalten werden. Die Rechte der Anleger*innen auf Zahlungen aus diesen Sicherheitserlösen sind der Zahlung bestimmter Kosten, Gebühren, Ausgaben und sonstiger im Zusammenhang mit dem Programm fälliger Beträge untergeordnet. Im Falle einer Verwertung oder Vollstreckung der Sicherheiten werden die Erlöse in der anwendbaren Rangfolge verwendet, nach der die den Anleger*innen geschuldeten Beträge bestimmten Kosten, Gebühren, Aufwendungen und anderen Beträgen, einschliesslich (ohne Einschränkung) der Kosten für die Liquidation der Sicherheiten, nachgeordnet sind, aber gegenüber den Forderungen anderer Gläubiger*innen der Emittentin Vorrang haben.

16. Wo werden die Wertpapiere gehandelt werden?

Die im Rahmen dieses Programms angebotenen Produkte werden nicht börsennotiert oder börsengehandelt.

17. Welches sind die Hauptrisiken, die mit den Wertpapieren verbunden sind?

Zugrunde liegende Vermögenswerte

Der Wert der Produkte wird durch den Preis und die Entwicklung des Basiswerts oder der Basiswertkomponenten beeinflusst. Der von der Emittentin bei der Rückzahlung der Produkte zu zahlende Betrag bzw. der Betrag der Sicherheiten, die zurückgezahlt werden können, hängt von der Wertentwicklung dieser Vermögenswerte ab, wie gemäss den Emissionsbedingungen berechnet. Die Produkte sind in keiner Weise kapitalgeschützt und es besteht daher das Risiko eines teilweisen oder vollständigen Verlustes der Investition.

Bei einem Produkt, das sich auf einen Korb von Basiswerten bezieht, kann die negative Entwicklung einer einzelnen Komponente die positive Entwicklung anderer Komponenten überwiegen und sich negativ auf die Rendite der Produkte auswirken.

Um das Gegenparteirisiko zu minimieren, wird nur der minimal notwendige Betrag (ca. 20 % des Vermögens) bei Kraken gehalten, hauptsächlich als Sicherheit für Krypto-Perpetuals und Krypto-Options. Überschüssige Mittel werden übertragen und in einer Custodial Wallet bei der Bank Frick oder auf einem Geldkonto bei der Bank Frick (einem regulierten Finanzinstitut im Europäischen Wirtschaftsraum) verwahrt.

18. Liquidität

Die Produkte werden nicht an einer Börse oder einem Handelsplatz notiert sein. Anlegende werden daher ihre Produkte nur auf bilateraler Basis (OTC) verkaufen können, wobei es keinen notierten Marktpreis für die Produkte gibt.

Durchführungsrisiko

Es besteht das Risiko, dass Geschäfte mit einem Basiswert nicht zu dem angegebenen Preis durchgeführt werden können. Etwaige Abweichungen zwischen dem angegebenen Preis und dem Ausführungspreis können auf die Verfügbarkeit von Vermögenswerten, etwaige relevante Spreads oder Gebühren an der Börse oder Diskrepanzen in der Preisbildung an verschiedenen Börsen zurückzuführen sein. Die Emittentin ergreift alle angemessenen Massnahmen, um eine optimale Ausführung zu gewährleisten, ist jedoch durch die KYC-Anforderungen, Verwahrungslösungen und die Verfügbarkeit von Börsenplätzen eingeschränkt. Die Emittentin kann daher nicht garantieren, dass der Preis, zu dem ein Handel ausgeführt wird, der beste weltweit verfügbare Preis ist.

Verwertung von Sicherheiten

Wenn die bei der Verwertung der Sicherheiten erhaltenen Beträge nicht ausreichen, um die Gebühren und Kosten des Programms und der beteiligten Parteien sowie die Zahlungsverpflichtungen der Emittentin gegenüber den Anleger*innen vollständig zu decken, können die Anleger*innen möglicherweise einen erheblichen Verlust erleiden.

D. Wesentliche Informationen über das öffentliche Angebot der Anleihen

19. Unter welchen Bedingungen und nach welchem Zeitplan kann ich in dieses Wertpapier investieren?

Der **AWMZ SP3 PZ Tracker** unterliegt einem fortlaufenden Emissions- und Rücknahmemechanismus, in dessen Rahmen zusätzliche Wertpapiere dieses Produkts emittiert und Wertpapiere von Anleger*innen gemäss den Emissionsbedingungen zurückgekauft werden können.

Die Emittentin akzeptiert Direktzeichnungen nur von regulierten Banken oder Brokern mit Sitz in der EU/dem EWR, der Schweiz oder dem Vereinigten Königreich, die berechtigt sind, direkt über SIX SIS AG zu handeln und welche die Definition einer professionellen Anlegerin oder eines professionellen Anlegers gemäss der SPB-Anordnung erfüllen («**zugelassene Anleger*innen**»). Andere Anleger*innen können die Wertpapiere direkt bei ihrer Bank oder ihrem Broker (sofern es sich um eine geeignete Anlegerin oder einen geeigneten Anleger handelt) oder auf dem Sekundärmarkt ausserbörslich (OTC) erwerben.

Die Emittentin kann jederzeit beschliessen, die Produkte zurückzukaufen (Call-Option). Zugelassene Anleger*innen können die Rücknahme durch die Emittentin verlangen, indem sie sich direkt an die Zahlstelle wenden. Die Rücknahme kann in einer Häufigkeit bzw. in Intervallen verlangt werden, die in den endgültigen Bedingungen für jedes Produkt festgelegt sind, und ist, sofern in den endgültigen Bedingungen nicht anders angegeben, in der Regel an die Bewertungshäufigkeit eines bestimmten Produkts gebunden.

Abrechnung

Die Abwicklung und Abrechnung von Geschäften mit den Wertpapieren erfolgt über die SIX SIS AG oder ein anderes in den endgültigen Bedingungen definiertes Clearing-System.

Kosten

Die Kosten für die Emission von Produkten im Rahmen des Programms werden von der Emittentin getragen und nicht vom Emissionserlös abgezogen.

Den Anleger*innen werden Verwaltungsgebühren, Depotgebühren, Indexlizenzgebühren, Anlageverwaltungsgebühren, Performancegebühren und andere Gebühren, die den Anbieter*innen von Dienstleistungen im Zusammenhang mit den Produkten zustehen (Anlegergebühren), in Rechnung gestellt, wie in den jeweiligen endgültigen Bedingungen näher beschrieben.

20. Warum wird dieses Prospekt erstellt?

10C PCC wurde gegründet, um strukturierte Produkte zu emittieren, die in Bezug auf ihre Protected Cells handeln, einschliesslich aktiv verwalteter Zertifikate, die an bestimmte Basiswerte gebunden sind. 10C PCC hat das in diesem Basisprospekt beschriebene Programm für strukturierte Anleihen und Zertifikate (das Programm) eingerichtet, unter dem von Zeit zu Zeit Produkte emittiert werden können.

Die Erlöse aus der Emission einer Serie von Anleihen werden nach Abzug von Kosten und Vermögenswerten, die für allgemeine Unternehmenszwecke benötigt werden, in bestimmte Basiswerte investiert, die als Sicherheiten für die Verpflichtungen der Emittentin aus diesem Basisprospekt dienen.

Die Nettoerlöse, welche die Emittentin durch die Emission von Produkten im Rahmen des Programms zu erzielen erwartet, sowie die geschätzten Kosten, die pro Produkt anfallen, werden in den endgültigen Bedingungen und der emissionsspezifischen Zusammenfassung für jedes Produkt angegeben.

Potenzielle Interessenkonflikte

Mehrere Teilnehmer*innen an den im Basisprospekt und in diesen endgültigen Bedingungen beschriebenen Transaktionen sind identisch oder stehen in enger Verbindung zueinander. Die Verwahrstelle fungiert gleichzeitig als Zahlstelle und Berechnungsstelle im Rahmen des Programms.

Es wurden geeignete Verfahren eingeführt, um Interessenkonflikte zu vermeiden, die sich nachteilig auf die Interessen der Anleger*innen auswirken. Die Gebühren, die an alle Parteien sowie an unabhängige Parteien zu zahlen sind, werden im Basisprospekt oder in den endgültigen Bedingungen offengelegt.